Grünenthal

Company snapshot

Grünenthal GmbH is a German [pharmaceutical company](en.wikipedia.org/wiki/Pharmaceutical_com) headquartered in [Aachen](en.wikipedia.org/wiki/Aachen) in Germany. It was founded in 1946 as Chemie Grünenthal and has been continuously [family-owned](en.wikipedia.org/wiki/Family_business). The company was the first to introduce [penicillin](en.wikipedia.org/wiki/Penicillin) into the German market in

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Grünenthal. Not investment advice.

• What is Grünenthal?

  Gruenenthal is a pharma organization headquartered in EU. Primary therapeutic focus areas include Moderate to severe pain associated with Osteoarthritis of the knee, Not applicable for phase I study. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent reco

• Is Grünenthal publicly traded?

  Grünenthal appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Grünenthal develop or market?

  We link 5 drug profile(s) where Grünenthal is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gruenenthal-gmbh#company-drugs.

• What are the latest developments for Grünenthal?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Grünenthal focus on?

  Grünenthal focuses on Moderate to severe pain associated with Osteoarthritis of the knee, Not applicable for phase I study based on our analysis of their pipeline programs and drug development activities.